Abbott Labs

ABT-N

NYSE:ABT

108.83
3.64 (3.46%)
Abbott Laboratories is a multinational health care company with headquarters in Lake Bluff, Illinois.
More at Wikipedia

Analysis and Opinions about ABT-N

Signal
Opinion
Expert
BUY
BUY
September 30, 2020
Their new 15-minute Covid test rallied today. The test works with an app that indicates the user passing the test, hence allowing the user to board planes among other things. This could be a game-changer. This is still a buy despite today's rally.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
September 30, 2020
Their new 15-minute Covid test rallied today. The test works with an app that indicates the user passing the test, hence allowing the user to board planes among other things. This could be a game-changer. This is still a buy despite today's rally.
PAST TOP PICK
PAST TOP PICK
September 15, 2020
(A Top Pick Sep 12/19, Up 28%) Still buying it around $102. It's a diversified healthcare company including nutritionals and generic drugs, the latter being sold to emerging markets. EM account for 40% of revenues. Medical devices was seeing fine product momentum even before Covid. After Covid, they've been producing testing kits which drives growth. They just announced a 5-minute test, boasting easy-to-use packaging, which will push growth. She expects excellent growth in the next few years, and it pays a solid dividend.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
September 15, 2020
(A Top Pick Sep 12/19, Up 28%) Still buying it around $102. It's a diversified healthcare company including nutritionals and generic drugs, the latter being sold to emerging markets. EM account for 40% of revenues. Medical devices was seeing fine product momentum even before Covid. After Covid, they've been producing testing kits which drives growth. They just announced a 5-minute test, boasting easy-to-use packaging, which will push growth. She expects excellent growth in the next few years, and it pays a solid dividend.
BUY
BUY
July 27, 2020
Biotech has been strong, so steer away from this and go to pharma. Abbot is on the verge of breaking out after basing. There's potential with their vaccine. Pays around 1.5% dividend. He doesn't expect politicians to pressure pharma stocks during this pandemic.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
July 27, 2020
Biotech has been strong, so steer away from this and go to pharma. Abbot is on the verge of breaking out after basing. There's potential with their vaccine. Pays around 1.5% dividend. He doesn't expect politicians to pressure pharma stocks during this pandemic.
WATCH
WATCH
July 22, 2020
The pharma sector has been a safe haven during the pandemic. With companies involved with COVID research, he is looking at this closely. He does not own it yet. They have great dividends, but growth has been slow and that problem will not go away anytime soon. Having exposure to pharma would be a good thing.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
July 22, 2020
The pharma sector has been a safe haven during the pandemic. With companies involved with COVID research, he is looking at this closely. He does not own it yet. They have great dividends, but growth has been slow and that problem will not go away anytime soon. Having exposure to pharma would be a good thing.
TOP PICK
TOP PICK
June 24, 2020
She is putting new client money into this last week. A diversified health care company with four divisions. They have a pharma group that sells into emerging markets. They also have a medical device, diagnostics and a nutritional division. They have developed both screening and antibody tests for COVID-19. Even if a vaccine is found, testing will be required for quite a while. They have increased their dividend for over 40 consecutive years. Yield 1.62% (Analysts’ price target is $100.75)
Show full opinionHide full opinion
Abbott Labs (ABT-N)
June 24, 2020
She is putting new client money into this last week. A diversified health care company with four divisions. They have a pharma group that sells into emerging markets. They also have a medical device, diagnostics and a nutritional division. They have developed both screening and antibody tests for COVID-19. Even if a vaccine is found, testing will be required for quite a while. They have increased their dividend for over 40 consecutive years. Yield 1.62% (Analysts’ price target is $100.75)
COMMENT
COMMENT
June 18, 2020

ABT-N vs. PFE-N. Abbot Labs has a Great franchise. Very well loved by the investment community. You are really not getting any opportunity to invest at a cheaper valuation. PFE-N is somewhat of a drug ETF. They have a big portfolio. You are bidding on their strategy of buying and selling drug lines. This one will be well positioned. The entry price is not the greatest but you could buy it and you would be fine.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
June 18, 2020

ABT-N vs. PFE-N. Abbot Labs has a Great franchise. Very well loved by the investment community. You are really not getting any opportunity to invest at a cheaper valuation. PFE-N is somewhat of a drug ETF. They have a big portfolio. You are bidding on their strategy of buying and selling drug lines. This one will be well positioned. The entry price is not the greatest but you could buy it and you would be fine.

PAST TOP PICK
PAST TOP PICK
May 13, 2020
(A Top Pick May 14/19, Up 25%) They have held this for years. Their diagnostic division has developed four different COVID testing products, including tests for antibodies. Their recent earnings reflect delays in device growth, which she was not surprised with. However, the diagnostics division is ramping up and benefiting with all the upcoming test requirements. She has been adding to portfolios around $90.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
May 13, 2020
(A Top Pick May 14/19, Up 25%) They have held this for years. Their diagnostic division has developed four different COVID testing products, including tests for antibodies. Their recent earnings reflect delays in device growth, which she was not surprised with. However, the diagnostics division is ramping up and benefiting with all the upcoming test requirements. She has been adding to portfolios around $90.
BUY
BUY
May 12, 2020
It was a pharma, but spun that operation off. What's left is a company in medical diagnostics. ABT bought two medical companies to build on that. A very good company with a long string of growing dividend payments, like 35 years. His only knock is that its PE has run, so watch that.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
May 12, 2020
It was a pharma, but spun that operation off. What's left is a company in medical diagnostics. ABT bought two medical companies to build on that. A very good company with a long string of growing dividend payments, like 35 years. His only knock is that its PE has run, so watch that.
PAST TOP PICK
PAST TOP PICK
January 14, 2020
(A Top Pick Jan 10/19, Up 25%) A diversified healthcare company that's done well. They sell generic drugs to higher-growth EM (40% of revenues); adult and child nutritional products; and medical products which is showing profit momentum driven by product launches. Aging demographics favour ABT. They don't suffer US drug pricing issues, either. They've increased their dividend for the last 47 years.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
January 14, 2020
(A Top Pick Jan 10/19, Up 25%) A diversified healthcare company that's done well. They sell generic drugs to higher-growth EM (40% of revenues); adult and child nutritional products; and medical products which is showing profit momentum driven by product launches. Aging demographics favour ABT. They don't suffer US drug pricing issues, either. They've increased their dividend for the last 47 years.
TOP PICK
TOP PICK
September 12, 2019
Diversified healthcare company, a space she likes. Not impacted by focus on drug pricing. Sell generics to emerging markets. Also a nutritional business and medical devices, which are growing. Has increased dividend 46-47 years in a row. Yield is 1.50%. (Analysts’ price target is $92.87)
Show full opinionHide full opinion
Abbott Labs (ABT-N)
September 12, 2019
Diversified healthcare company, a space she likes. Not impacted by focus on drug pricing. Sell generics to emerging markets. Also a nutritional business and medical devices, which are growing. Has increased dividend 46-47 years in a row. Yield is 1.50%. (Analysts’ price target is $92.87)
WATCH
WATCH
August 22, 2019
They spun off Abvee that produces Humeria that represents 60% of ABT-T. It was the most successful drug in the world. The area they made acquisitions in have been successful. It is a well managed company. It is not inexpensive. 25 times earnings. When something rises like this then if the earnings don't keep up, the multiples goes up. It is a high valuation stock so be cautious.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
August 22, 2019
They spun off Abvee that produces Humeria that represents 60% of ABT-T. It was the most successful drug in the world. The area they made acquisitions in have been successful. It is a well managed company. It is not inexpensive. 25 times earnings. When something rises like this then if the earnings don't keep up, the multiples goes up. It is a high valuation stock so be cautious.
DON'T BUY
DON'T BUY
August 13, 2019

The PFE-N non-patent drugs will be dilutive for earnings in the short term. She prefers either JNJ-N or ABT-N

Show full opinionHide full opinion
Abbott Labs (ABT-N)
August 13, 2019

The PFE-N non-patent drugs will be dilutive for earnings in the short term. She prefers either JNJ-N or ABT-N

BUY WEAKNESS
BUY WEAKNESS
July 10, 2019
Healthcare has had a good run. They have medical devices and are diversified globally. Don't chase it.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
July 10, 2019
Healthcare has had a good run. They have medical devices and are diversified globally. Don't chase it.
BUY
BUY
May 30, 2019
It is a very fine company. They have increased dividends for about 45 years in succession. They are very predictable. They spun off their pharmaceutical division in 2013. They reinvented themselves by buying a heart medication company, a diagnostic company and a strong nutrition business.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
May 30, 2019
It is a very fine company. They have increased dividends for about 45 years in succession. They are very predictable. They spun off their pharmaceutical division in 2013. They reinvented themselves by buying a heart medication company, a diagnostic company and a strong nutrition business.
TOP PICK
TOP PICK
May 14, 2019
A diversified healthcare company. Their medical devices and diagnostic division is doing quite well with many new products. Pays a good dividend of 1.7% that they have increased for past decades. She likes this space. ABT has good growth. (Analysts’ price target is $83.05)
Show full opinionHide full opinion
Abbott Labs (ABT-N)
May 14, 2019
A diversified healthcare company. Their medical devices and diagnostic division is doing quite well with many new products. Pays a good dividend of 1.7% that they have increased for past decades. She likes this space. ABT has good growth. (Analysts’ price target is $83.05)
Showing 1 to 15 of 128 entries

Abbott Labs(ABT-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 6

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 6

Stockchase rating for Abbott Labs is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Abbott Labs(ABT-N) Frequently Asked Questions

What is Abbott Labs stock symbol?

Abbott Labs is a American stock, trading under the symbol ABT-N on the New York Stock Exchange (ABT). It is usually referred to as NYSE:ABT or ABT-N

Is Abbott Labs a buy or a sell?

In the last year, 6 stock analysts published opinions about ABT-N. 6 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for Abbott Labs.

Is Abbott Labs a good investment or a top pick?

Abbott Labs was recommended as a Top Pick by Jim Cramer - Mad Money on 2020-09-30. Read the latest stock experts ratings for Abbott Labs.

Why is Abbott Labs stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Abbott Labs worth watching?

6 stock analysts on Stockchase covered Abbott Labs In the last year. It is a trending stock that is worth watching.

What is Abbott Labs stock price?

On 2020-09-30, Abbott Labs (ABT-N) stock closed at a price of $108.83.